Alkermes plc (ALKS)

Acerca de Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Al 3 de noviembre de 2026, la acción de Alkermes plc (ALKS) subió con fuerza a $47.10, un alza de 4.93% (+$2.22) frente al cierre anterior. En la sesión, las acciones han operado entre $45.22 y $47.43. Eso ubica a ALKS en el tercio superior de su rango de 52 semanas, de $27.00 a $55.67. Alkermes plc opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $7.53 mil millones, con cerca de 716.1 mil acciones negociadas.

Últimas noticias de ALKS

• Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to SayYahoo Finance· 3 nov, 8:30 a.m. ET
• Alkermes (ALKS) Surpasses Q3 Earnings and Revenue EstimatesYahoo Finance· 3 nov, 7:15 a.m. ET
• Alkermes: Q3 Earnings SnapshotYahoo Finance· 3 nov, 7:12 a.m. ETAP
• Alkermes plc Reports Third Quarter 2026 Financial ResultsYahoo Finance· 3 nov, 7:05 a.m. ET
• Axsome Sinks 10% Despite Q3 Revenue Beat “Surpassing a One-Billion-Dollar Annual Run Rate”tikr.com· 2 nov, 1:56 p.m. ET
• Alkermes (ALKS) Starts Phase 2 MDD Trial, Is The Upside Already Priced In?Yahoo Finance· 31 oct, 2:15 a.m. ET
• Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)Yahoo Finance· 30 oct, 7:00 a.m. ETMDDADHD
• Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesYahoo Finance· 29 oct, 9:30 a.m. ETALNY

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de ALKS en un solo lugar? Crea una cuenta gratis →

• https://www.marketbeat.com/earnings/reports/2026-11-4-alkermes-plc-stock/ $ALKS Alkermes Earnings Transcript

  @EarningsInsider· 3 nov, 9:16 a.m. ET

• $ALKS Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.09 down -81.63% YoY • Reported revenue of $480.13M up 21.80% YoY • Alkermes reiterated its financial expectations for 2026, as set forth in its July 28, 2026 press release; this filing does not state quant…

  @StocktwitsEarnings· 3 nov, 8:11 a.m. ET

• WOW! A very large, unusual order came in on $ALKS. - $1.1M+ purchased of the $55 call for Jan. 21st, 2028. Betting on about 40% upside in the next 15 months.

  @Peloswings_04· 15 oct, 5:18 p.m. ET

• WOW! A very large, unusual order came in on $ALKS. - $1.1M+ purchased of the $55 call for Jan. 21st, 2028. Betting on about 40% upside in the next 15 months.

  @peloswing· 15 oct, 3:31 p.m. ET

• $ALKS reclaimed its 200DMA and supporting trendline today! Over $1.2M in premium hit the tape for January 2028 $55 Calls! 😲 This is a beautiful set up for the long term - immediate target at ~$43!

  @theoptionsplug· 15 oct, 3:30 p.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →